Empowered Funds LLC Acquires 1,720 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Empowered Funds LLC grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,408 shares of the medical research company’s stock after purchasing an additional 1,720 shares during the period. Empowered Funds LLC’s holdings in Thermo Fisher Scientific were worth $5,935,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Farmers & Merchants Investments Inc. raised its holdings in shares of Thermo Fisher Scientific by 4.4% in the 4th quarter. Farmers & Merchants Investments Inc. now owns 4,082 shares of the medical research company’s stock worth $2,124,000 after buying an additional 173 shares in the last quarter. Kingsview Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 9.1% during the fourth quarter. Kingsview Wealth Management LLC now owns 20,297 shares of the medical research company’s stock valued at $10,559,000 after acquiring an additional 1,694 shares during the period. Apollon Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 16.8% in the 4th quarter. Apollon Wealth Management LLC now owns 12,899 shares of the medical research company’s stock worth $6,711,000 after purchasing an additional 1,857 shares during the last quarter. Vest Financial LLC lifted its holdings in Thermo Fisher Scientific by 13.5% during the 4th quarter. Vest Financial LLC now owns 1,839 shares of the medical research company’s stock valued at $957,000 after purchasing an additional 219 shares during the last quarter. Finally, Cidel Asset Management Inc. grew its stake in Thermo Fisher Scientific by 3.0% during the fourth quarter. Cidel Asset Management Inc. now owns 1,313 shares of the medical research company’s stock worth $683,000 after buying an additional 38 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on TMO shares. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price on the stock in a report on Friday, January 10th. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Barclays dropped their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Finally, Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $658.00.

Thermo Fisher Scientific Trading Down 1.4 %

NYSE TMO opened at $545.27 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock’s 50-day moving average is $547.81 and its 200-day moving average is $571.95. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The firm has a market cap of $208.57 billion, a P/E ratio of 32.99, a P/E/G ratio of 3.18 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This represents a 1.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock valued at $11,231,699 over the last three months. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.